Key result
Quinidine dosing increases digitoxin plasma concentrations by ~45% and prolongs elimination half-life.
Why the study?
The effect of quinidine on digitoxin pharmacokinetics is controversial due to lack of studies in subjects at steady-state conditions.
Does quinidine affect digitoxin pharmacokinetics and pharmacodynamics in healthy subjects at steady state?
Does quinidine affect digitoxin pharmacokinetics and pharmacodynamics in healthy subjects at steady state?
Quinidine significantly increases digitoxin plasma concentrations by decreasing total and extrarenal clearance, highlighting a clinically important drug-drug interaction.
Answers are grounded in this paper and cite their sources.
May warrant digitoxin level monitoring with quinidine; leaves open confirmation of interaction magnitude in patients.
Quinidine has been reported to increase digoxin plasma concentrations, which increases the risk of digoxin overdose. The effect of quinidine on digitoxin pharmacokinetics is still controversial because most studies were not performed with subjects achieving definite steady-state conditions. To determine whether quinidine affects digitoxin kinetics and cardiac efficacy, we measured glycoside plasma concentrations and renal excretion as well as ECG parameters and systolic time intervals before and during quinidine dosing in eight healthy subjects at steady state. Mean (+/- SD) digitoxin plasma concentrations and renal excretion increased from 13.6 +/- 2.2 ng/ml and 16.1 +/- 5.8 micrograms/24 hours before dosing to 19.7 +/- 3.1 ng/ml and 23.4 +/- 4.9 micrograms/24 hours, respectively, during quinidine dosing for 32 days. While renal digitoxin clearance was not noticeably changed by quinidine, total digitoxin clearance and extrarenal digitoxin clearance decreased by an average of 32% and 40.5%, respectively. The elimination t1/2 was prolonged from 150.3 +/- 20.6 to 202.6 +/- 37.5 hours. The increased digitoxin plasma level is pharmacodynamically active. We conclude that there is a clinically important interaction between digitoxin and quinidine, but it is to a lesser extent and is caused by different mechanism, in part, than the interaction between digoxin and quinidine.
No takes yet. Share an insight, caveat, or question.
Kuhlmann et al. (1986) studied Healthy subjects (n=8). Quinidine vs. Before quinidine dosing (baseline) was evaluated on Digitoxin plasma concentrations (ng/ml). Quinidine dosing for 32 days increased mean digitoxin plasma concentrations from 13.6 to 19.7 ng/ml and prolonged elimination half-life from 150.3 to 202.6 hours.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: